Pharma's new top lobbyist is former Majority Leader Eric Cantor
📍 How it ended
The Pharmaceutical Research and Manufacturers of America (PhRMA) named former House Majority Leader Eric Cantor as its new president and CEO. Cantor's appointment was announced on September 29, with multiple sources confirming his selection as the organization's top lobbyist. The story quieted without further developments reported in the coverage.
Epilogue added 3h ago, after coverage quieted.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
- Velocity & Diffusion: Coverage escalated across 5 distinct news outlets with 5 published articles, achieving a live velocity of 14.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Pharma's new top lobbyist is former Majority Leader Eric Cantor" developed substantial multi-source reporting across the Business sector, tracked across 5 distinct newsrooms by Newsylist.
Key reporting was led by Fierce Pharma, Endpoints News, U.S. News & World Report and Axios. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.
Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 3h ago.
Coverage (5)
-
-
-
-
-
Pharma's new top lobbyist is former Majority Leader Eric Cantor Politico · 35d ago broke it first
Questions people are asking
What drove coverage for Pharma's new top lobbyist is former Majority Leader Eric Cantor?
Coverage spiked when 5 independent newsrooms published 5 verified reports during this coverage cycle.
How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.